Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01780389 · ClinicalTrials.gov registry record · Phase 4
Open-label Milnacipran for Persistent Knee Pain One Year After Total Knee Arthroplasty (TKA)
A Phase 4 study of Knee Pain After Total Knee Arthroplasty and Osteoarthritis Pain, sponsored by Duke University.
- Completed
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT01780389 is a Phase 4 study of Knee Pain After Total Knee Arthroplasty and Osteoarthritis Pain that has completed, run by Duke University. The registered enrollment target is 5 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01780389, a Phase 4 study of Knee Pain After Total Knee Arthroplasty and Osteoarthritis Pain, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
The current study examines the effects of milnacipran in patients who have chronic persistent knee pain one year or longer after total knee arthroplasty (TKA) to evaluate for a pain-relieving effect.
Conditions Studied
Interventions
- DRUG Open-label flexibly dosed milnacipran
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2010-10 |
| Est. Completion | 2011-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01780389
The ClinicalTrials.gov registry entry for NCT01780389 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Knee Pain After Total Knee Arthroplasty appearing as the primary indexed condition, and to 1 intervention - of which Open-label flexibly dosed milnacipran is the first listed.
NCT01780389 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT01780389 about?
NCT01780389 is a clinical study titled "Open-label Milnacipran for Persistent Knee Pain One Year After Total Knee Arthroplasty (TKA)". The current study examines the effects of milnacipran in patients who have chronic persistent knee pain one year or longer after total knee arthroplasty (TKA) to evaluate for a pain-relieving effect.
What is the current status of trial NCT01780389?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2010-10. Estimated completion is 2011-07.
What conditions does trial NCT01780389 study?
This clinical trial studies the following conditions: Knee Pain After Total Knee Arthroplasty, Osteoarthritis Pain.
What interventions are being tested in trial NCT01780389?
The interventions under investigation include: Open-label flexibly dosed milnacipran (DRUG).
Who is sponsoring clinical trial NCT01780389?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01780389 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Knee Pain After Total Knee Arthroplasty
All registered trials for this condition
Osteoarthritis Pain
All registered trials for this condition
North Carolina
All trials with a study site in North Carolina
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.